Cargando…
Impact of Advanced Radiotherapy on Second Primary Cancer Risk in Prostate Cancer Survivors: A Nationwide Cohort Study
PURPOSE: External Beam Radiotherapy (EBRT) techniques dramatically changed over the years. This may have affected the risk of radiation-induced second primary cancers (SPC), due to increased irradiated low dose volumes and scatter radiation. We investigated whether patterns of SPC after EBRT have ch...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662556/ https://www.ncbi.nlm.nih.gov/pubmed/34900722 http://dx.doi.org/10.3389/fonc.2021.771956 |
_version_ | 1784613462064758784 |
---|---|
author | Jahreiß, Marie-Christina Heemsbergen, Wilma D. van Santvoort, Bo Hoogeman, Mischa Dirkx, Maarten Pos, Floris J. Janssen, Tomas Dekker, Andre Vanneste, Ben Minken, Andre Hoekstra, Carel Smeenk, Robert J. van Oort, Inge M. Bangma, Chris H. Incrocci, Luca Aben, Katja K. H. |
author_facet | Jahreiß, Marie-Christina Heemsbergen, Wilma D. van Santvoort, Bo Hoogeman, Mischa Dirkx, Maarten Pos, Floris J. Janssen, Tomas Dekker, Andre Vanneste, Ben Minken, Andre Hoekstra, Carel Smeenk, Robert J. van Oort, Inge M. Bangma, Chris H. Incrocci, Luca Aben, Katja K. H. |
author_sort | Jahreiß, Marie-Christina |
collection | PubMed |
description | PURPOSE: External Beam Radiotherapy (EBRT) techniques dramatically changed over the years. This may have affected the risk of radiation-induced second primary cancers (SPC), due to increased irradiated low dose volumes and scatter radiation. We investigated whether patterns of SPC after EBRT have changed over the years in prostate cancer (PCa) survivors. MATERIALS AND METHODS: PCa survivors diagnosed between 1990-2014 were selected from the Netherlands Cancer Registry. Patients treated with EBRT were divided in three time periods, representing 2-dimensional Radiotherapy (RT), 3-dimensional conformal RT (3D-CRT), and the advanced RT (AdvRT) era. Standardized incidence ratios (SIR) and absolute excess risks (AER) were calculated to estimate relative and excess absolute SPC risks. Sub-hazard ratios (sHRs) were calculated to compare SPC rates between the EBRT and prostatectomy cohort. SPCs were categorized by subsite and anatomic region. RESULTS: PCa survivors who received EBRT had an increased risk of developing a solid SPC (SIR=1.08; 1.05-1.11), especially in patients aged <70 years (SIR=1.13; 1.09-1.16). Pelvic SPC risks were increased (SIR=1.28; 1.23-1.34), with no obvious differences between the three EBRT eras. Non-pelvic SPC were only significantly increased in the AdvRT era (SIR=1.08; 1.02-1.14), in particular for the 1-5 year follow-up period. Comparing the EBRT cohort to the prostatectomy cohort, again an increased pelvic SPC risk was found for all EBRT periods (sHRs= 1.61, 1.47-1.76). Increased non-pelvic SPC risks were present for all RT eras and highest for the AdvRT period (sHRs=1.17, 1.06-1.29). CONCLUSION: SPC risk in patients with EBRT is increased and remained throughout the different EBRT eras. The risk of developing a SPC outside the pelvic area changed unfavorably in the AdvRT era. Prolonged follow-up is needed to confirm this observation. Whether this is associated with increased irradiated low-dose volumes and scatter, or other changes in clinical EBRT practice, is the subject of further research. |
format | Online Article Text |
id | pubmed-8662556 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86625562021-12-11 Impact of Advanced Radiotherapy on Second Primary Cancer Risk in Prostate Cancer Survivors: A Nationwide Cohort Study Jahreiß, Marie-Christina Heemsbergen, Wilma D. van Santvoort, Bo Hoogeman, Mischa Dirkx, Maarten Pos, Floris J. Janssen, Tomas Dekker, Andre Vanneste, Ben Minken, Andre Hoekstra, Carel Smeenk, Robert J. van Oort, Inge M. Bangma, Chris H. Incrocci, Luca Aben, Katja K. H. Front Oncol Oncology PURPOSE: External Beam Radiotherapy (EBRT) techniques dramatically changed over the years. This may have affected the risk of radiation-induced second primary cancers (SPC), due to increased irradiated low dose volumes and scatter radiation. We investigated whether patterns of SPC after EBRT have changed over the years in prostate cancer (PCa) survivors. MATERIALS AND METHODS: PCa survivors diagnosed between 1990-2014 were selected from the Netherlands Cancer Registry. Patients treated with EBRT were divided in three time periods, representing 2-dimensional Radiotherapy (RT), 3-dimensional conformal RT (3D-CRT), and the advanced RT (AdvRT) era. Standardized incidence ratios (SIR) and absolute excess risks (AER) were calculated to estimate relative and excess absolute SPC risks. Sub-hazard ratios (sHRs) were calculated to compare SPC rates between the EBRT and prostatectomy cohort. SPCs were categorized by subsite and anatomic region. RESULTS: PCa survivors who received EBRT had an increased risk of developing a solid SPC (SIR=1.08; 1.05-1.11), especially in patients aged <70 years (SIR=1.13; 1.09-1.16). Pelvic SPC risks were increased (SIR=1.28; 1.23-1.34), with no obvious differences between the three EBRT eras. Non-pelvic SPC were only significantly increased in the AdvRT era (SIR=1.08; 1.02-1.14), in particular for the 1-5 year follow-up period. Comparing the EBRT cohort to the prostatectomy cohort, again an increased pelvic SPC risk was found for all EBRT periods (sHRs= 1.61, 1.47-1.76). Increased non-pelvic SPC risks were present for all RT eras and highest for the AdvRT period (sHRs=1.17, 1.06-1.29). CONCLUSION: SPC risk in patients with EBRT is increased and remained throughout the different EBRT eras. The risk of developing a SPC outside the pelvic area changed unfavorably in the AdvRT era. Prolonged follow-up is needed to confirm this observation. Whether this is associated with increased irradiated low-dose volumes and scatter, or other changes in clinical EBRT practice, is the subject of further research. Frontiers Media S.A. 2021-11-26 /pmc/articles/PMC8662556/ /pubmed/34900722 http://dx.doi.org/10.3389/fonc.2021.771956 Text en Copyright © 2021 Jahreiß, Heemsbergen, van Santvoort, Hoogeman, Dirkx, Pos, Janssen, Dekker, Vanneste, Minken, Hoekstra, Smeenk, van Oort, Bangma, Incrocci and Aben https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Jahreiß, Marie-Christina Heemsbergen, Wilma D. van Santvoort, Bo Hoogeman, Mischa Dirkx, Maarten Pos, Floris J. Janssen, Tomas Dekker, Andre Vanneste, Ben Minken, Andre Hoekstra, Carel Smeenk, Robert J. van Oort, Inge M. Bangma, Chris H. Incrocci, Luca Aben, Katja K. H. Impact of Advanced Radiotherapy on Second Primary Cancer Risk in Prostate Cancer Survivors: A Nationwide Cohort Study |
title | Impact of Advanced Radiotherapy on Second Primary Cancer Risk in Prostate Cancer Survivors: A Nationwide Cohort Study |
title_full | Impact of Advanced Radiotherapy on Second Primary Cancer Risk in Prostate Cancer Survivors: A Nationwide Cohort Study |
title_fullStr | Impact of Advanced Radiotherapy on Second Primary Cancer Risk in Prostate Cancer Survivors: A Nationwide Cohort Study |
title_full_unstemmed | Impact of Advanced Radiotherapy on Second Primary Cancer Risk in Prostate Cancer Survivors: A Nationwide Cohort Study |
title_short | Impact of Advanced Radiotherapy on Second Primary Cancer Risk in Prostate Cancer Survivors: A Nationwide Cohort Study |
title_sort | impact of advanced radiotherapy on second primary cancer risk in prostate cancer survivors: a nationwide cohort study |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662556/ https://www.ncbi.nlm.nih.gov/pubmed/34900722 http://dx.doi.org/10.3389/fonc.2021.771956 |
work_keys_str_mv | AT jahreißmariechristina impactofadvancedradiotherapyonsecondprimarycancerriskinprostatecancersurvivorsanationwidecohortstudy AT heemsbergenwilmad impactofadvancedradiotherapyonsecondprimarycancerriskinprostatecancersurvivorsanationwidecohortstudy AT vansantvoortbo impactofadvancedradiotherapyonsecondprimarycancerriskinprostatecancersurvivorsanationwidecohortstudy AT hoogemanmischa impactofadvancedradiotherapyonsecondprimarycancerriskinprostatecancersurvivorsanationwidecohortstudy AT dirkxmaarten impactofadvancedradiotherapyonsecondprimarycancerriskinprostatecancersurvivorsanationwidecohortstudy AT posflorisj impactofadvancedradiotherapyonsecondprimarycancerriskinprostatecancersurvivorsanationwidecohortstudy AT janssentomas impactofadvancedradiotherapyonsecondprimarycancerriskinprostatecancersurvivorsanationwidecohortstudy AT dekkerandre impactofadvancedradiotherapyonsecondprimarycancerriskinprostatecancersurvivorsanationwidecohortstudy AT vannesteben impactofadvancedradiotherapyonsecondprimarycancerriskinprostatecancersurvivorsanationwidecohortstudy AT minkenandre impactofadvancedradiotherapyonsecondprimarycancerriskinprostatecancersurvivorsanationwidecohortstudy AT hoekstracarel impactofadvancedradiotherapyonsecondprimarycancerriskinprostatecancersurvivorsanationwidecohortstudy AT smeenkrobertj impactofadvancedradiotherapyonsecondprimarycancerriskinprostatecancersurvivorsanationwidecohortstudy AT vanoortingem impactofadvancedradiotherapyonsecondprimarycancerriskinprostatecancersurvivorsanationwidecohortstudy AT bangmachrish impactofadvancedradiotherapyonsecondprimarycancerriskinprostatecancersurvivorsanationwidecohortstudy AT incrocciluca impactofadvancedradiotherapyonsecondprimarycancerriskinprostatecancersurvivorsanationwidecohortstudy AT abenkatjakh impactofadvancedradiotherapyonsecondprimarycancerriskinprostatecancersurvivorsanationwidecohortstudy |